Yu‐Ting Chou

2.8k total citations
62 papers, 2.1k citations indexed

About

Yu‐Ting Chou is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yu‐Ting Chou has authored 62 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 31 papers in Oncology and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yu‐Ting Chou's work include Lung Cancer Treatments and Mutations (17 papers), Cancer Cells and Metastasis (10 papers) and Lung Cancer Research Studies (9 papers). Yu‐Ting Chou is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cancer Cells and Metastasis (10 papers) and Lung Cancer Research Studies (9 papers). Yu‐Ting Chou collaborates with scholars based in Taiwan, United States and China. Yu‐Ting Chou's co-authors include Cheng‐Wen Wu, Shih‐Hwa Chiou, Mong‐Lien Wang, Han-Sui Hsu, Chun-Fu Hong, Wang-Ju Hsieh, Yingshan Chen, Tzu-Wei Lin, Chi‐Jen Chen and Sey‐En Lin and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and The EMBO Journal.

In The Last Decade

Yu‐Ting Chou

58 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yu‐Ting Chou Taiwan 24 1.3k 779 662 362 244 62 2.1k
Xiaohong Yao China 26 1.2k 0.9× 783 1.0× 614 0.9× 160 0.4× 550 2.3× 43 2.1k
He Zhou China 30 1.4k 1.1× 687 0.9× 808 1.2× 323 0.9× 854 3.5× 78 2.6k
Aiping Luo China 29 1.8k 1.3× 598 0.8× 998 1.5× 243 0.7× 296 1.2× 66 2.5k
Yadi Wu China 16 1.1k 0.8× 493 0.6× 316 0.5× 140 0.4× 172 0.7× 32 1.6k
Vasilena Gocheva United States 21 1.3k 1.0× 969 1.2× 1.2k 1.7× 141 0.4× 601 2.5× 25 2.7k
Wen Cheng China 28 1.1k 0.8× 406 0.5× 683 1.0× 418 1.2× 449 1.8× 99 2.1k
David S. Garlick United States 21 993 0.7× 355 0.5× 378 0.6× 347 1.0× 244 1.0× 35 1.6k
Jinguan Lin China 19 1.3k 0.9× 382 0.5× 891 1.3× 277 0.8× 370 1.5× 42 1.9k
Hongzhen Li United States 20 712 0.5× 639 0.8× 267 0.4× 394 1.1× 182 0.7× 61 1.6k
Zhaojin Yu China 23 1.1k 0.8× 532 0.7× 490 0.7× 128 0.4× 286 1.2× 63 1.7k

Countries citing papers authored by Yu‐Ting Chou

Since Specialization
Citations

This map shows the geographic impact of Yu‐Ting Chou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu‐Ting Chou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu‐Ting Chou more than expected).

Fields of papers citing papers by Yu‐Ting Chou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu‐Ting Chou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu‐Ting Chou. The network helps show where Yu‐Ting Chou may publish in the future.

Co-authorship network of co-authors of Yu‐Ting Chou

This figure shows the co-authorship network connecting the top 25 collaborators of Yu‐Ting Chou. A scholar is included among the top collaborators of Yu‐Ting Chou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu‐Ting Chou. Yu‐Ting Chou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Lin‐Yu, Yu‐Ting Chou, Phui‐Ly Liew, et al.. (2024). In vitro drug testing using patient-derived ovarian cancer organoids. Journal of Ovarian Research. 17(1). 194–194. 2 indexed citations
2.
Wang, Yuanxin, et al.. (2024). Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted Therapy. Cancers. 16(8). 1558–1558. 10 indexed citations
3.
Chen, Wan‐Ting, Chi‐Li Chung, Yu‐Ting Chou, et al.. (2022). Comparative survival analysis of platinum‐based adjuvant chemotherapy for early‐stage squamous cell carcinoma and adenocarcinoma of the lung. Cancer Medicine. 11(10). 2067–2078. 13 indexed citations
4.
Chou, Yu‐Ting, Yen‐Chun Koh, Kalyanam Nagabhushanam, Chi‐Tang Ho, & Min‐Hsiung Pan. (2021). A Natural Degradant of Curcumin, Feruloylacetone Inhibits Cell Proliferation via Inducing Cell Cycle Arrest and a Mitochondrial Apoptotic Pathway in HCT116 Colon Cancer Cells. Molecules. 26(16). 4884–4884. 13 indexed citations
5.
Chen, Cheng‐Chieh, et al.. (2021). Evaluation of the diagnostic accuracy of bronchial brushing cytology in lung cancer: A meta‐analysis. Cancer Cytopathology. 129(9). 739–749. 15 indexed citations
6.
Chien, Chu‐Yen, Chung‐Cheng Chen, Chia‐Chen Hsu, et al.. (2021). YAP-Dependent BiP Induction Is Involved in Nicotine-Mediated Oral Cancer Malignancy. Cells. 10(8). 2080–2080. 15 indexed citations
7.
Hsiao, Shih-Hsin, et al.. (2020). Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR–TKI Tolerance and Lung Cancer Dissemination. Cancer Research. 80(20). 4426–4438. 43 indexed citations
8.
Chen, Kuan‐Wei, et al.. (2020). PIP3 depletion rescues myoblast fusion defects in human rhabdomyosarcoma cells. Journal of Cell Science. 133(8). 4 indexed citations
9.
Chih, Ya‐Han, et al.. (2020). Antimicrobial Peptides with Enhanced Salt Resistance and Antiendotoxin Properties. International Journal of Molecular Sciences. 21(18). 6810–6810. 18 indexed citations
10.
Wu, Chia‐Chang, Pei‐Yu Chen, Sheng-Chieh Lin, et al.. (2020). Critical role of SOX2–IGF2 signaling in aggressiveness of bladder cancer. Scientific Reports. 10(1). 8261–8261. 25 indexed citations
11.
Yu, Huiyuan, Chih‐Lung Wu, Hsi-Tsung Cheng, et al.. (2019). <p>A novel CXCL8 analog is effective in inhibiting the growth via cell cycle arrest and attenuating invasion of Lewis lung carcinoma</p>. OncoTargets and Therapy. Volume 12. 7611–7621. 5 indexed citations
12.
13.
Wen, Kuo‐Chang, Pi‐Lin Sung, Yu‐Ting Chou, et al.. (2017). The role of EpCAM in tumor progression and the clinical prognosis of endometrial carcinoma. Gynecologic Oncology. 148(2). 383–392. 35 indexed citations
14.
Chou, Yu‐Ting, Shih Sheng Jiang, Junn-Liang Chang, et al.. (2016). Epigenetic Switch between SOX2 and SOX9 Regulates Cancer Cell Plasticity. Cancer Research. 76(23). 7036–7048. 52 indexed citations
15.
Hsiao, Shih-Hsin, Horng-Chyuan Lin, Yu‐Ting Chou, et al.. (2013). Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients. Lung Cancer. 81(3). 455–461. 40 indexed citations
16.
Chen, Yi‐Chen, Chih‐Ming Pan, Yu‐Wei Chang, et al.. (2013). The PML isoform IV is a negative regulator of nuclear EGFR’s transcriptional activity in lung cancer. Carcinogenesis. 34(8). 1708–1716. 16 indexed citations
17.
Chou, Yu‐Ting, et al.. (2012). CITED2 functions as a molecular switch of cytokine-induced proliferation and quiescence. Cell Death and Differentiation. 19(12). 2015–2028. 61 indexed citations
18.
Chou, Yu‐Ting, Yung-Chang Lien, Yuan‐Hung Wang, et al.. (2010). EGFR Promotes Lung Tumorigenesis by Activating miR-7 through a Ras/ERK/Myc Pathway That Targets the Ets2 Transcriptional Repressor ERF. Cancer Research. 70(21). 8822–8831. 232 indexed citations
19.
Chiou, Shih‐Hwa, Mong‐Lien Wang, Yu‐Ting Chou, et al.. (2010). Coexpression of Oct4 and Nanog Enhances Malignancy in Lung Adenocarcinoma by Inducing Cancer Stem Cell–Like Properties and Epithelial–Mesenchymal Transdifferentiation. Cancer Research. 70(24). 10433–10444. 496 indexed citations
20.
Chou, Yu‐Ting, et al.. (2009). MAD2B, a Novel TCF4-binding Protein, Modulates TCF4-mediated Epithelial-Mesenchymal Transdifferentiation. Journal of Biological Chemistry. 284(29). 19613–19622. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaohong Yao Breakdown of academic impact, for papers by He Zhou Breakdown of academic impact, for papers by Aiping Luo Breakdown of academic impact, for papers by Yadi Wu Breakdown of academic impact, for papers by Vasilena Gocheva Breakdown of academic impact, for papers by Wen Cheng Breakdown of academic impact, for papers by David S. Garlick Breakdown of academic impact, for papers by Jinguan Lin Breakdown of academic impact, for papers by Hongzhen Li Breakdown of academic impact, for papers by Zhaojin Yu
Rankless by CCL
2026